Genome Screening Co. KSQ Therapeutics Appoints Chris Heberlig as CFO

Aitechpark14 May, 2021Technology

KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics? discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, today announced the appointment of Chris Heberlig, MBA, as Chief Financial Officer. ?Chris is an seasoned biotech finance executive who brings deep experience in the areas of corporate finance and operations with growing biopharma companies like KSQ,? said Qasim Rizvi, Chief Executive Officer of KSQ Therapeutics. ?We are thrilled to have him join our team at this pivotal time in KSQ?s growth trajectory. Our CRISPRomics platform has expansive potential across therapeutic areas and modalities. As we continue to expand and progress our pipeline, his experience will be invaluable.?